Novartis AG (NVS): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Novartis fell $0.84 (-1.1%) to $73.45 on average volume. Throughout the day, 1,232,363 shares of Novartis exchanged hands as compared to its average daily volume of 1,428,000 shares. The stock ranged in price between $73.16-$73.64 after having opened the day at $73.35 as compared to the previous trading day's close of $74.29. Other companies within the Drugs industry that declined today were:
(
), down 16.7%,
(
), down 12.5%,
Catalyst Pharmaceutical Partners
(
TheStreet Recommends
), down 12.4% and
(
), down 6.8%.
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $183.8 billion and is part of the health care sector. Shares are up 17.4% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.
TheStreet Ratings rates
Novartis
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Novartis Ratings Report.
On the positive front,
(
), up 24.4%,
(
), up 17.6%,
(
), up 13.1% and
(
), up 10.7% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
